Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/30/2003CA2481499A1 Use of cyclopamine in the treatment of psoriasis and other skin disorders
10/30/2003CA2481467A1 Dry powder compositions
10/30/2003CA2481120A1 Method for treating and preventing hyperparathyroidism
10/30/2003CA2481088A1 Use of materials having zinc ionophoric behavior
10/30/2003CA2480451A1 New 2-substituted -1,3-thiazole compounds
10/30/2003CA2480437A1 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/30/2003CA2480404A1 Fc receptor homolog, reagents, and uses thereof
10/30/2003CA2480325A1 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2478991A1 Compositions and methods for augmenting kidney function
10/30/2003CA2476792A1 Methods of simultaneously treating ocular rosacea and acne rosacea
10/30/2003CA2384474A1 Compositions and methods for protecting against sexually transmitted diseases
10/29/2003WO2002092081A1 Method of treatment
10/29/2003EP1357125A2 Process for the preparation of halogenated derivatives of vinca alcaloids
10/29/2003EP1357122A2 Oxazolidinone compounds and pharmaceutical compositions containing them
10/29/2003EP1357121A1 Azaring-ether deritatives and their use as nicotinic ach receptor modulators
10/29/2003EP1357120A1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
10/29/2003EP1357116A1 2-acylaminothiazole derivative or its salt
10/29/2003EP1357111A1 Pyridone derivative having affinity for cannabinoid 2-type receptor
10/29/2003EP1356824A2 88KDA tumorigenic growth factor and antagonists
10/29/2003EP1356820A1 DNA vaccine combined with an inducer of tumor cell apoptosis
10/29/2003EP1356818A2 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites
10/29/2003EP1356817A1 Therapeutic and/or preventive agents for diseases due to retinal ischemia
10/29/2003EP1356816A1 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
10/29/2003EP1356815A1 Analgesic and antiinflammatory drugs
10/29/2003EP1356814A1 Pharmaceutical emulsion preparation
10/29/2003EP1356813A1 Antibacterial compositions comprising metal phthalocyanine analogues
10/29/2003EP1356812A1 Medicines for treatment and prevention of neurogenic pain
10/29/2003EP1356811A1 Preventives or remedies for arthritis
10/29/2003EP1356810A1 TNFa PRODUCTION INHIBITORS
10/29/2003EP1356806A1 A pharmaceutical composition for treating dysmenorrhea and premature labor
10/29/2003EP1356284A2 Schizophrenia related genes
10/29/2003EP1356278A2 Methods and compositions for the identification and treatment of neurodegenerative disorders
10/29/2003EP1356108A2 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
10/29/2003EP1356105A2 Method for identifying compounds or lead structures against rna target motifs and rna/protein interactions
10/29/2003EP1356092A2 Compositions and methods for the therapy and diagnosis of ovarian cancer
10/29/2003EP1356091A2 Method of detecting inflammatory lung disorders
10/29/2003EP1356071A2 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/29/2003EP1356070A2 Conditionally replicating viral vectors and their use
10/29/2003EP1356053A2 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
10/29/2003EP1356052A2 Prokaryotically produced antibodies and uses thereof
10/29/2003EP1356026A2 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
10/29/2003EP1355934A2 Compositions and methods relating to lung specific genes and proteins
10/29/2003EP1355922A2 Stress proteins and peptides and methods of use thereof
10/29/2003EP1355921A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
10/29/2003EP1355916A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
10/29/2003EP1355910A1 Formulation of boronic acid compounds
10/29/2003EP1355909A2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
10/29/2003EP1355908A1 New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them
10/29/2003EP1355907A1 Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
10/29/2003EP1355906A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
10/29/2003EP1355905A1 Pyrazole compounds useful as protein kinase inhibitors
10/29/2003EP1355904A2 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
10/29/2003EP1355903A1 Pyrazole derivatives against tgf overexpression
10/29/2003EP1355902A1 Sulfonamide compounds, their preparation and use
10/29/2003EP1355900A2 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
10/29/2003EP1355899A1 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
10/29/2003EP1355894A1 Amidinophenylalanine derivatives as thrombin inhibitors
10/29/2003EP1355893A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion
10/29/2003EP1355892A1 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors
10/29/2003EP1355891A2 Therapy
10/29/2003EP1355889A1 Substituted triazole diamine derivatives as kinase inhibitors
10/29/2003EP1355888A1 Quinazolinone derivatives
10/29/2003EP1355887A1 Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
10/29/2003EP1355886A1 Fused heterocyclic compounds
10/29/2003EP1355885A1 Pyridine derivatives useful as cyclooxygenase inhibitor
10/29/2003EP1355884A1 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
10/29/2003EP1355881A2 An improved process for preparing pure ondansetron hydrochloride dihydrate
10/29/2003EP1355878A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/29/2003EP1355877A1 Process of obtaining compositions of stable lutein and lutein derivatives
10/29/2003EP1355875A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
10/29/2003EP1355873A1 Pleuromutilin derivatives with antimicrobial activity
10/29/2003EP1355870A1 Thiazolamines and their use as tgf-beta inhibitors
10/29/2003EP1355698A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
10/29/2003EP1355672A2 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
10/29/2003EP1355671A2 Water-soluble polymer conjugates of triazine derivatives
10/29/2003EP1355669A2 Augmented cognitive training
10/29/2003EP1355666A2 Use of rgm and its modulators
10/29/2003EP1355665A2 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/29/2003EP1355658A1 Pyk2 phosphorylation by her3 induces tumor invasion
10/29/2003EP1355654A1 Lower alcohol-insoluble extract of hovenia dulcis var. koreana nakai, a polysaccharide isolated therefrom and an antihepatotoxic composition containing same
10/29/2003EP1355652A2 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
10/29/2003EP1355651A2 Treatment of diabetes mellitus using vardenafil
10/29/2003EP1355650A1 New combination of active ingredients containing alfuzosine and apomorphine
10/29/2003EP1355649A2 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
10/29/2003EP1355647A2 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
10/29/2003EP1355646A1 Muscarinic receptor agonists
10/29/2003EP1355645A2 Method for treating fibrotic diseases or other indications iiic
10/29/2003EP1355644A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia
10/29/2003EP1355643A2 Epoxyvibsanin b
10/29/2003EP1355642A2 INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS
10/29/2003EP1355641A2 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
10/29/2003EP1355640A1 Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds
10/29/2003EP1355639A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/29/2003EP1355638A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
10/29/2003EP1355637A2 Inhibitors of matriptase for the treatment of cancer
10/29/2003EP1355636A1 Transdermal therapeutic system for administering non-steroidal antiphlogistic agents containing carboxyl groups, and a method for the production of the same
10/29/2003EP1355635A1 New film coating
10/29/2003EP1355634A2 Sn-38 lipid complexes and methods of use
10/29/2003EP1355633A1 New film coating
10/29/2003EP1355632A1 Amlodipine free base
1 ... 5294 5295 5296 5297 5298 5299 5300 5301 5302 5303 5304 5305 5306 5307 5308 5309 5310 5311 5312 5313 5314 ... 7860